Pharmaceuticals News and Research

RSS

OPKO Health acquires Pharmacos Exakta

OPKO Health, Inc. today announced that it has completed the acquisition of Pharmacos Exakta, S.A. de C.V. (“Pharmacos Exakta”), a privately-owned Mexican pharmaceutical company engaged in the manufacture, marketing and distribution of ophthalmic and other pharmaceutical products for government and private markets since 1957. OPKO acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of OPKO Common Stock.

18 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.

18 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

Taro Pharmaceutical Industries to discontinue manufacturing operations in Roscrea, Ireland

Taro Pharmaceutical Industries Ltd. today announced that it will discontinue manufacturing operations at the sterile manufacturing facility of its Irish subsidiary, Taro Pharmaceuticals Ireland Limited, in Roscrea, Ireland (“Taro Ireland”).

18 Feb 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME).

18 Feb 2010

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

West Pharmaceutical Services, Inc. today announced its results for the fourth quarter and full year of 2009.

18 Feb 2010

ScienceWorksForUS reveals how Recovery Act science funding benefits their campuses and communities

On the first anniversary of the American Recovery and Reinvestment Act (ARRA) - the economic stimulus - the nation's research universities today provided nearly 100 examples of how a relatively small element of the measure is paying outsize short- and long-term dividends for the nation. Of the $787 billion contained in the ARRA, $21.5 billion is allocated for research and science infrastructure.

18 Feb 2010

INC Research creates management program for strategic clinical delivery alliances with pharma and biotechnology customers

INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, has created an Alliance Partnerships program dedicated to the creation and management of strategic clinical delivery alliances with pharmaceutical and biotechnology customers. Tim Dietlin has been appointed VP, Alliance Development to lead this effort on structuring alliance relationships based on joint strategic objectives rather than service level agreements.

18 Feb 2010

NPG becomes official media partner to the 2010 WIN Symposium

Nature Publishing Group (NPG) is the official media partner to the 2010 WIN (Worldwide Innovative Networking) Symposium, it was announced today. The second annual WIN Symposium, which will be held in the Palais des Congrès, Paris, 7–9 July 2010, will bring together hundreds of oncology researchers from around the world to discuss how best to tailor therapies for patients with cancer.

18 Feb 2010

Patient-centered medical home concept to benefit pharmaceutical industry

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that the pharmaceutical industry stands to gain from the patient-centered medical home concept that continues to gain traction across the country. According to the recent New England Health Plan Analysis, medical home projects seek to maintain costs and improve health through better treatment compliance, including prescription drug regimens.

18 Feb 2010

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets from the country’s various sources. The task force has also recommended HUNT Biosciences be a model for the national company.

18 Feb 2010

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.

18 Feb 2010

AMRI announces Excelsyn acquisition

AMRI today announced the acquisition of Excelsyn Ltd., a well recognized leader in providing chemical development and manufacturing services to the pharmaceutical industry in Europe. Located in Holywell, North Wales, UK, Excelsyn has 60 employees and generated revenue of $15 million in 2009.

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Aptuit develops proprietary production screen to understand API and drug formulations

Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.

18 Feb 2010

Rondaxe and TD2 announce cancer drug development alliance

TGen Drug Development (TD2) and Rondaxe Enterprises today announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

18 Feb 2010

US health plans adopt unified approach to assist consumers in appropriate medication use

Dozens of US health plans nationwide have adopted a unified approach to assist seniors and other consumers to appropriately use medications. The move follows increased emphasis from the federal government for Medicare plans to offer more robust Medication Therapy Management (“MTM”) programs in 2010.

18 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Medivir reports 2009 financial results

Medivir had a very satisfactory 2009. Our cold sore product secured market approval in the US and Europe and is well positioned for launch. This will take place under the XerclearTM trademark in Europe, and under the XereseTM trademark in the US during 2010.

18 Feb 2010

Pharmaceuticals News and Research

OPKO Health acquires Pharmacos Exakta

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Taro Pharmaceutical Industries to discontinue manufacturing operations in Roscrea, Ireland

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

ScienceWorksForUS reveals how Recovery Act science funding benefits their campuses and communities

INC Research creates management program for strategic clinical delivery alliances with pharma and biotechnology customers

NPG becomes official media partner to the 2010 WIN Symposium

Patient-centered medical home concept to benefit pharmaceutical industry

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

AMRI announces Excelsyn acquisition

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Aptuit develops proprietary production screen to understand API and drug formulations

Rondaxe and TD2 announce cancer drug development alliance

US health plans adopt unified approach to assist consumers in appropriate medication use

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Medivir reports 2009 financial results

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence